



PRODUCT: **Gamifant®**

COMPANY: Sobi

THERAPEUTIC AREA & INDICATION:

First treatment for infants/adults with primary haemophagocytic lymphohistiocytosis (HLH), an ultra-rare immune disorder that leads to severe inflammation, infections, bleeding, organ failures and early death

ABOUT THE PRODUCT

Gamifant® (emapalumab-lzsg) is the first and only medicine approved by the FDA for primary haemophagocytic lymphohistiocytosis (HLH), an ultra-rare syndrome of hyperinflammation that can rapidly become fatal unless diagnosed and treated. Gamifant is indicated for paediatric and adult primary HLH patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy.

Visit [www.gamifant.com](http://www.gamifant.com) for more information, including full Prescribing Information.